Wednesday, 14 August 2013

Patient education on proper adherence of diet chart, life style modifications by diabetologists, daily aerobic & physical exercises, brisk walking daily for half an hour as routine, awareness about identifying minor symptoms & providing guideline of prevention of hypoglycemia play a vital role in influencing the diabetic mind in the community – instead of prescribing very costly newer but not time tested OHA agents like Pioglitazone / Rosiglitazone/ gliptins/ or Dipeptidyl peptidase-4 inhibitors [long term effects of this drugs are still unknown] and Metformin is the time tested drug to treat Type-2 Diabetics with least chance of hypoglycemia

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here×

Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

      Re: Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

      13 August 2013

      Title:
      Patient education on proper adherence of diet chart, life style modifications by diabetologists, daily aerobic & physical exercises, brisk walking daily for half an hour as routine, awareness about identifying minor symptoms & providing guideline of prevention of hypoglycemia play a vital role in influencing the diabetic mind in the community – instead of prescribing very costly newer but not time tested OHA agents like Pioglitazone / Rosiglitazone/ gliptins/ or Dipeptidyl peptidase-4 inhibitors [long term effects of this drugs are still unknown] and Metformin is the time tested drug to treat Type-2 Diabetics with least chance of hypoglycemia
      Severe hypoglycemia is a well established potential risk factor for cardiovascular diseases resulting in silent Acute Myocardial Infraction and fatal cardiac arrhythmia in people with type 2 DM without other comorbid conditions and risk factors like older age, sex, cigarette smoking, hyperlipidimia, obesity, microalbuminia, hyperuricimia, diabetic nephropathy & metabolic syndromes and poorly controlled glycemic index. Many RCT trials also cautioned us that intensive glucose control with Insulin or various modern newer OHA Sulphonurias (SU), including recently withdrawn from USA market Rosiglitazone & Pioglitazone by FDA, was associated with risk of fatal myocardial infarction in people with type 2 DM. The ACCORD study[1] or ADVANCE study in 2011 [2] or VADT study [3] also provided us information since 2010 onwards on relative increased risks (22% as per ACCORD) for CVS mortality in Type2 DM when associated with hypoglycemia and indicated that severe hypoglycemia was strongly associated with a higher risk of cardiovascular disease and mortality. Intensive & tight glucose control thus must not be the main goal of controlling of HBA1c at non diabetic level [HBA1c 5%-6%] and it is rather better to maintain HbA1c between 6.5 % to <7% by the clinicians, giving advice to his patients accordingly. Education of common public in community is thus important in this regard. Severe hypoglycemia has acute effects on sympatho-adrenal activation, inflammation, and endothelial dysfunction, all of which have potential adverse cardiovascular effects including enhanced atherosclerosis. In addition, cardiac ischemia or fatal arrhythmias occuring during hypoglycemia may be responsible for the increased risk of cardiovascular death among patients with severe hypoglycemia. Avoiding hypoglycemia is thus very important to prevent cardiovascular death, and less stringent glycemic control targets may be thus considered for people with type 2 DM who are at high risk of hypoglycemia and aged more than 60 years.
      Glucose lowering drugs with a low propensity to induce hypoglycemia (for example, best drug according to me is metformin) should be considered as first line choice to avoid hypoglycemia. Metformin has been prescribed for the type2 diabetic patients for more than 50 years if not more & it is time tested best drug. Long term studies and data with Metformin are also completely now available. Metformin has minimal GI side effects like nausea & vomiting, diarrhea, and it lowers appetite. It lowers the body weight also. It is also the drug of choice for impaired Glucose tolerance patients too. In most patients if started slowly or extended release Metformin is given as first line drug. The cost of treatment is also low in India. Importantly, severe hypoglycemic episodes are preceded by only change in food intake. However caution must be taken when creatinine level >130mg and eGFr less than 45.
      The Second line of Drug is DPP4 inhibitors [Dipeptidyl peptidase-4 inhibitors-100 mg daily as sitagliptin] along with Metformin for adults. Meta-analysis of DPP-4 inhibitors agonists does not increase cardiac mortality or serious adverse events, GI intolerances like nausea, vomiting, diarrhea during its short term studies, it does not cause weight gain, it lowers HbA1c [DPP-4 inhibitors monotherapy are actually associated with a smaller decline in HbA1c], does not cause hypoglycemia, but it may cause nasopharyngitis, UTI and URTI and the drug is very costly in Indian market. Pioglitazone also significantly reduces HBA1c while achieving no positive impact on cardiovascular outcomes, but rather it increases the risk of heart failure. Rosiglitazone also reduces HbA1c but it also increases heart failure and increases risk of myocardial infarction and cardiovascular death. If one’s goals include fewer adverse outcomes, reduced cardiovascular mortality, and a reduction in complications from diabetes, I personally see no advantage of prescribing habit and in Indian diabetologists trend is to prescribe these agents over less expensive pharmacologic options like metformin for some unknown reason.
      Fewer hypoglycemia episodes can be expected with DPP-4 inhibitors when these drugs are compared with other sulfonylureas, but not compared with the drug metformin. This group of drugs may be effective alternatives for patients with type 2 diabetes for whom weight gain is a de-motivating factor or who are troubled by hypoglycemic episodes .Also, this helps to postpone the use of insulin in patients who are intolerant to metformin or in whom metformin becomes failure or is contraindicated as most of the DPP-4s are licensed for use in low eGFR. Though US-FDA has approved this group of drugs in patients with type-2 DM [please note that DPP-4 inhibitors have not been included in the 2009 American Diabetes Association and the European Association for the study of Diabetes consensus algorithm], the exact position of these drugs in treatment of type-2 DM is still undefined. The exact long term effects of these drugs are still unknown. The National Institute for Health and Clinical Excellence (NICE)[4] clinical guideline for type 2 diabetes suggests adding a DPP-4 inhibitor instead of a sulfonylurea as second line treatment to first line metformin when there is a considerable risk for hypoglycemia or if a sulfonylurea is contraindicated or not tolerated by patient] .
      Glycemic control with gliptins like sitagliptin[50 to 100 mg daily dose], vildagliptin, saxagliptin, and linagliptin may look slightly inferior to metformin for glycemic control, but weight neutrality and almost nil hypoglycemia makes this group of drugs superior to SUs on balance. GLP-1 analogue seems to be most promising second line drug after metformin failure. One of the serious side effects cautioned currently with sitagliptin is pancreatitis - the severe forms, hemorrhagic or necrotizing pancreatitis in patients using sitagliptin and pancreatic cancer. US FDA has approved the use of sitagliptin in combination with metformin marketed in India as trade name JANUMET.
      But to me the best treatment options for type2 diabetes interventions are diet [Fiber containing low calorie diet], daily aerobic exercise, yoga, brisk walking on road or manual workers, control of BMI, weight and medications with Metformin.
      Finally, study should be done with effect of hypoglycemia and risk of cardiovascular mortality in type 1 DM also.
      References
      1] Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
      2] Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-8.
      3]Duckworth WC, Abraira C, Moritz TE, Davis SN, Emanuele N, Goldman S, et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial.
      J Diabetes Complications2011;25:355-61
      4]Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyper-glycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
      Competing interests: None declared
      Copy Right- Copy Right of this Rapid Response in Journal BMJ  belongs to Professor Pranab kumar Bhattacharya and his first degree relatives only as per copy right act & rules of Intellectual Property Right Rules 3D/107/1201 a,b/ RDF Copy Right rules/ SPARC copy Right rules-2006/ and Protect intellectual Property Right(PIP) copy right rules of USA-2012.Please do not Infringe and be enough careful for your own safety if you are not direct Blood relation to prof Pranab Kumar Bhattacharya  . No person, No NGOS [ except the authors& first degree relatives] No drug Houses or No Phermaceuticcal personales, no researchers   in the state of West Bengal or in any states of India or in any abroad countries are authorized ever to use this article, with any meaning full,  scientific sentences or with scientific and meaning full words laid out in this article either in the class room/  or in mass teaching programme including CME  or  in any form what so ever it is with any content of this article or while in writing any book or for his/her personal/ home use, or collective works or for any future Research or implementation as a policy matter or,[ except the authors ]or  by Xeroxing and distributing the article/ or by printing/saving/broadcasting the article from any website of internet services,displayed without proper copy right clearance from the authors or from his family members or future copy right owner by written forms. 
      Sd/ Professor (Dr.) Pranab kumar Bhattacharya WBMES
      Professor Pranab Kumar Bhattacharya MD, Professor &Head, Dept. of Pathology, [Convener, Course Coordinator, in charge of Diploma in clinical Pathology(DCP) course of West Bengal University of Health Sciences(WBUHS); In charge of Diploma in laboratory technology WBUHS Member & Member Secretary of Board of studies of WBUHS for pathology & DCP courses ]
      School of Tropical Medicine, Kolkata, 108 CR Avenue; Kolkata-00073; West Bengal; India , 108 Chittaranjan Avenue Kolkata-700073; West Bengal; India
      Click to like:
      at

      No comments:

      Post a Comment